SEC Form 4 · accession 0000899243-16-029283
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick J Mahaffy
Officer — President and CEO · Director
Period of report
Sep 16, 2016
Accepted (ET)
Sep 19, 2016 · 6:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $79.05 | Sep 16, 2016 | J | 25,000 | D | — | Mar 2, 2025 | Common Stock | 25,000 | 75,000 | D |
Explanation of responses
- F1The Reporting Person voluntarily forfeited the option as to 25,000 of the shares, which was subject to vesting upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rociletinib. Following such forfeiture, the Reporting Person holds the option as to the remaining 75,000 shares (the "Remaining Shares"). The option vested as to 12,500 of such Remaining Shares on March 2, 2016 and has vested or will vest as to 37,500 of such Remaining Shares in substantially equal installments over the 12 quarters immediately following such date. The option shall vest as to 25,000 of such Remaining Shares upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rucaparib.